Country: United States
Language: English
Source: NLM (National Library of Medicine)
LINEZOLID (UNII: ISQ9I6J12J) (LINEZOLID - UNII:ISQ9I6J12J)
Teva Pharmaceuticals USA Inc
LINEZOLID
LINEZOLID 600 mg
ORAL
PRESCRIPTION DRUG
Linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [see Warnings and Precautions (5.4) ]. Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [see Clinical Studies (14) ]. Community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [see Clinical Studies (14) ]. Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , or Strept
Linezolid tablets are available as follows: 600 mg (white, capsule-shaped, film-coated tablet debossed with "LZD" on one side and "600" on the other.) Store at 25ºC (77ºF). Protect from light. Keep bottles tightly closed to protect from moisture.
New Drug Application Authorized Generic
LINEZOLID- LINEZOLID TABLET, FILM COATED TEVA PHARMACEUTICALS USA INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LINEZOLID SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LINEZOLID. LINEZOLID TABLETS INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia (1.1); Community-acquired pneumonia (1.1); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis (1.2); Uncomplicated skin and skin structure infections (1.2); Vancomycin-resistant _Enterococcus faecium_ infections. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.4) DOSAGE AND ADMINISTRATION DOSAGE, ROUTE, AND FREQUENCY OF ADMINISTRATION INFE C TIO N PEDIATRIC PATIENTS (BIRTH THROUGH11YEARS OF AGE) ADULTS AND ADOLESCENTS (12 YEARS AND OLDER) DURATIO N (DAYS) Nosocomial pneumonia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 10 to 14 Community-acquired pneumonia, including concurrent bacteremia Complicated skin and skin structure infe ctions Vancomycin-resistant _Enterococcus_ _faecium_ infections_, _including concurrent bacte re mia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 14 to 28 Uncomplicated skin and skin structure infe ctions less than 5 yrs: 10 mg/kg oral every 8 hours 5–11 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral every 12 hours Adolescents: 600 mg oral every 12 hours 10 to 14 DOSAGE FORMS AND STRENGTHS Tablet: 600 mg linezolid. (3) CONTRAINDICATIONS Known hypersensitivity to linezolid or any of the other product co Read the complete document